MedTrace Logo

Effects of Apelin on the Lung Circulation in Pulmonary Hypertension

NCT01457170 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2013-07-15

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of Apelin on the lung circulation. The investigators hypothesise that Apelin will relax the lung blood vessels and improve the pumping ability of the heart.

Conditions

Interventions

DRUG

Apelin

During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.

DRUG

Saline (Placebo)

During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.

DRUG

Saline (Placebo)

During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.

DRUG

Apelin

During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.

Sponsors & Collaborators

  • NHS Lothian

    collaborator OTHER_GOV

  • Imperial College Healthcare NHS Trust

    collaborator OTHER

  • Golden Jubilee National Hospital

    lead OTHER_GOV

Principal Investigators

  • Andrew J Peacock, BSc MPhil MD · National Health Service: Golden Jubilee National Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01457170 on ClinicalTrials.gov